Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Using a patient-derived fibroblast ciliation assay to perform high throughput drug screen and candidate therapeutic compound validation for Bardet-Biedl syndrome (BBS)
EF 2020-21
Résumé
Bardet-Biedl syndrome (BBS) is a rare autosomal recessive genetic disorder caused by defective structure and/or function of the primary cilia. BBS is characterized by developmental anomalies, obesity, and a progressive retinal degeneration. Most BBS patients are legally blind in their teenage years, and many also suffer from autism, kidney and liver impairment, as well as digit and genitourinary anomalies. There are no treatments for BBS. Twenty-four genes are associated with BBS and BBS10 is one of the most commonly involved. The aim of my project will be to use a cellular assay with BBS10-patient-derived fibroblasts that show abnormal cilia. Imaging of that anomaly will be used to perform screening of previously approved drugs aiming to improve the cilia defect. We successfully established 4 genetically distinct fibroblast cell lines from different BBS10-patients and identified a structural phenotype of reduced and abnormal ciliation. After automating the reading of the cilia defect, in collaboration with the SPARC facility at SickKids, I will perform high throughput drug screens to identify drug candidates that rescue this ""decreased ciliation"" phenotype. Candidate compounds will expose new molecular pathways which will be validated using silencing approaches. The strongest candidate compounds will be shared with collaborators to be tested in their BBS10 mice and iPSC-derived retina sheets models. This novel approach could identify molecules that may slow the retinal degeneration for BBS10 patients who are currently going blind, and perhaps help for their other problems. This could lead the way for a Phase I clinical trial to prevent blindness in BBS patients. This approach may also be used for a growing number of cilia defect-related diseases.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449358
Name
Pearson Alexander L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Using a patient-derived fibroblast ciliation assay to perform high throughput drug screen and candidate therapeutic compound validation for Bardet-Biedl syndrome (BBS)
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bardet-Biedl Syndrome; Blindness; Ciliopathy; Fibroblasts; Genetic Disease; High Throughput Drug Screen; Pharmaceutical; Therapeutics
Abstract
Bardet-Biedl syndrome (BBS) is a rare autosomal recessive genetic disorder caused by defective structure and/or function of the primary cilia. BBS is characterized by developmental anomalies, obesity, and a progressive retinal degeneration. Most BBS patients are legally blind in their teenage years, and many also suffer from autism, kidney and liver impairment, as well as digit and genitourinary anomalies. There are no treatments for BBS. Twenty-four genes are associated with BBS and BBS10 is one of the most commonly involved. The aim of my project will be to use a cellular assay with BBS10-patient-derived fibroblasts that show abnormal cilia. Imaging of that anomaly will be used to perform screening of previously approved drugs aiming to improve the cilia defect. We successfully established 4 genetically distinct fibroblast cell lines from different BBS10-patients and identified a structural phenotype of reduced and abnormal ciliation. After automating the reading of the cilia defect, in collaboration with the SPARC facility at SickKids, I will perform high throughput drug screens to identify drug candidates that rescue this ""decreased ciliation"" phenotype. Candidate compounds will expose new molecular pathways which will be validated using silencing approaches. The strongest candidate compounds will be shared with collaborators to be tested in their BBS10 mice and iPSC-derived retina sheets models. This novel approach could identify molecules that may slow the retinal degeneration for BBS10 patients who are currently going blind, and perhaps help for their other problems. This could lead the way for a Phase I clinical trial to prevent blindness in BBS patients. This approach may also be used for a growing number of cilia defect-related diseases.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pearson, Alexander L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~